2882 SAND HILL ROAD, MENLO PARK, CA
Investor Presentation
Financial Results, Reg. FD
Summit Therapeutics Enters $380M Distribution Agreement with J.P. Morgan
Summit Therapeutics Inc. Annual Meeting - Director Elections and Auditor Rati...
Summit Therapeutics Withdraws Proposed Public Offering Due to Market Conditions
Other Events
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence